Cardiol Therapeutics (TSE:CRDL) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Cardiol Therapeutics (TSE:CRDL) in a research note issued to investors on Monday morning, BayStreet.CA reports.

Cardiol Therapeutics Stock Performance

TSE CRDL opened at C$2.44 on Monday. The company has a fifty day moving average price of C$2.26 and a 200-day moving average price of C$1.60. The firm has a market cap of C$158.87 million, a price-to-earnings ratio of -5.67 and a beta of 0.75. The company has a debt-to-equity ratio of 0.52, a current ratio of 5.29 and a quick ratio of 6.84. Cardiol Therapeutics has a 1 year low of C$0.74 and a 1 year high of C$2.94.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis.